Opinions
The Panic-Proof Portfolio (Stockchase Research)
Harmony Biosciences Holdings Inc
HRMY-Q
PAST TOP PICK
Sep 16, 2025
Stock price when the opinion was issued
You might be interested:
Premium contentHRMY is a bio-pharma company that has developed cannabis based CBD gels in the US. It is making potentially great strides on developing a treatment for narcolepsy. It trades at 14x earnings, 2.8x book and supports a 24% ROE. Cash reserves are growing, while debt is retired. We recommend setting a stop-loss at $30, looking to achieve $49 -- upside potential of 37%. Yield 0%
(Analysts’ price target is $49.70)Premium contentWe reiterate this commercial stage pharma company focusing on neurological treatment as a TOP PICK. It has a long runway of projects in the development pipeline and its histamine focused foundation treatment continues to create positive cash flow and growing cash reserves. We recommend trailing up the stop (from $30) to $33, looking to achieve $50 -- upside potential of 33%. Yield 0%
(Analysts’ price target is $50.55)
Our PAST TOP PICK with HRMY has triggered its stop at $33. To remain disciplined, we recommend covering the position at this time.